المؤلفون: Prins, Femke M, Hidding, Iwan J, Klaassen, Marjolein A Y, Collij, Valerie, Schultheiss, Johannes P D, Uniken Venema, Werna T C, Bangma, Amber, Aardema, Jurne B, Jansen, Bernadien H, Mares, Wout G N, Witteman, Ben J M, Festen, Eleonora A M, Dijkstra, Gerard, Visschedijk, Marijn C, Fidder, Herma H, Vich Vila, Arnau, Oldenburg, Bas, Gacesa, Ranko, Weersma, Rinse K

المساهمون: MS MDL 1, Cancer, Infection & Immunity

مصطلحات موضوعية: Adult, Antibodies, Monoclonal, Humanized/therapeutic use, Bacteria/genetics, Biological Therapy/methods, Biomarkers/analysis, Feces/microbiology, Female, Gastrointestinal Microbiome/drug effects, Humans, Inflammatory Bowel Diseases/drug therapy, Male, Metabolome/drug effects, Middle Aged, Prospective Studies, Treatment Outcome, Ustekinumab/therapeutic use, Journal Article

وصف الملف: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/455546

الاتاحة: https://dspace.library.uu.nl/handle/1874/455546

المصدر: BADBIR study groups & BSTOP Study Group 2024 , ' The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis : a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) ' , The British journal of dermatology , vol. 190 , no. 5 , ljad481 , pp. 689-700 . https://doi.org/10.1093/bjd/ljad481

مصطلحات موضوعية: Adalimumab/therapeutic use, Adjuvants, Immunologic/therapeutic use, Adult, Biological Factors/therapeutic use, Biological Products/therapeutic use, Cohort Studies, Dermatologists, Etanercept/therapeutic use, HLA-C Antigens, Humans, Immunologic Factors/therapeutic use, Psoriasis/drug therapy, Registries, Treatment Outcome, Ustekinumab/therapeutic use

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

Relation: https://research.manchester.ac.uk/en/publications/bddbf68f-8ef0-439a-afc6-233123c922ad

الاتاحة: https://research.manchester.ac.uk/en/publications/bddbf68f-8ef0-439a-afc6-233123c922ad
https://doi.org/10.1093/bjd/ljad481
https://pure.manchester.ac.uk/ws/files/296739563/BJD-2023-0747-Manuscript_Clean.docx

المؤلفون: Bertelsen, T, Egeberg, A, Skov, L, Rasmussen, M, Bryld, L, Funding, A, Ajgeiy, K, Aagaard, D Thein

المصدر: Bertelsen , T , Egeberg , A , Skov , L , Rasmussen , M , Bryld , L , Funding , A , Ajgeiy , K & Aagaard , D T 2024 , ' Drug survival of biologic therapies for palmoplantar pustulosis : A nationwide study ' , Journal of the European Academy of Dermatology and Venereology , vol. 38 , no. 2 , pp. 332-339 . https://doi.org/10.1111/jdv.19584

مصطلحات موضوعية: Adalimumab/adverse effects, Biological Factors/therapeutic use, Biological Products/therapeutic use, Biological Therapy, Humans, Prospective Studies, Psoriasis/drug therapy, Treatment Outcome, Ustekinumab/therapeutic use

وصف الملف: application/pdf

Relation: https://portal.findresearcher.sdu.dk/da/publications/4a357bdb-7408-42f1-9108-11cec7ce9f3d

الاتاحة: https://portal.findresearcher.sdu.dk/da/publications/4a357bdb-7408-42f1-9108-11cec7ce9f3d
https://doi.org/10.1111/jdv.19584
https://findresearcher.sdu.dk/ws/files/254162829/Acad_Dermatol_Venereol_-_2023_-_Bertelsen_-_Drug_survival_of_biologic_therapies_for_palmoplantar_pustulosis_A_nationwide.pdf

المؤلفون: Reenaers, Catherine, Louis, Edouard

المصدر: Revue Médicale de Liège, 77 (5-6), 323-329 (2022-05)

مصطلحات موضوعية: Tumor Necrosis Factor Inhibitors, FU77B4U5Z0 (Ustekinumab), Colitis, Ulcerative/drug therapy, Crohn Disease, Humans, Inflammatory Bowel Diseases/drug therapy, Ustekinumab/therapeutic use, New biologics, Small molecules, Treat, Ulcerative colitis, Crohn’s disease, target, to, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

Relation: https://rmlg.uliege.be/article/3625?lang=en; urn:issn:0370-629X; urn:issn:2566-1566

URL الوصول: https://orbi.uliege.be/handle/2268/301022

المؤلفون: Corbett, Mark, Ramessur, Ravi, Marshall, David, ACENCIO, Marcio Luis, OSTASZEWSKI, Marek, Barbosa, Ines A, Dand, Nick, Di Meglio, Paola, Haddad, Salma, Jensen, Andreas H M, Koopmann, Witte, Mahil, Satveer K, Rahmatulla, Seher, Rastrick, Joe, Saklatvala, Jake, Weidinger, Stephan, Wright, Kath, Eyerich, Kilian, Barker, Jonathan N, Ndlovu, Matladi, Conrad, Curdin, Skov, Lone, Smith, Catherine H, BIOMAP consortium

المصدر: British Journal of Dermatology, 187 (4), 494 - 506 (2022-10)

مصطلحات موضوعية: Biological Products, Biomarkers, CARD Signaling Adaptor Proteins, HLA-C Antigens, Lipopolysaccharides, Membrane Proteins, NF-kappa B, Tumor Necrosis Factor Inhibitors, CARD14 protein, human, Guanylate Cyclase, Ustekinumab, Humans, Proteomics, Ustekinumab/therapeutic use, Biological Products/therapeutic use, Psoriasis/therapy, Psoriasis, Dermatology, Human health sciences, Immunology & infectious disease, Sciences de la santé humaine, Immunologie & maladie infectieuse

Relation: urn:issn:0007-0963; urn:issn:1365-2133; https://orbilu.uni.lu/handle/10993/57442; info:hdl:10993/57442; https://orbilu.uni.lu/bitstream/10993/57442/1/treatresponse.pdf; info:pmid:35606928; wos:000827887200001

الاتاحة: https://orbilu.uni.lu/handle/10993/57442
https://orbilu.uni.lu/bitstream/10993/57442/1/treatresponse.pdf
https://doi.org/10.1111/bjd.21677

المؤلفون: Radtke, M., Conrad, C., Schuster, C., Saure, D., Mert, C., Riedl, E., Costanzo, A.

المصدر: The Journal of dermatological treatment, vol. 33, no. 2, pp. 1168-1170

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized/therapeutic use, Duration of Therapy, Humans, Psoriasis/drug therapy, Severity of Illness Index, Treatment Outcome, Ustekinumab/therapeutic use

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/32530342; info:eu-repo/semantics/altIdentifier/eissn/1471-1753; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C9A7B7A0C7243; https://serval.unil.ch/notice/serval:BIB_C9A7B7A0C724; https://serval.unil.ch/resource/serval:BIB_C9A7B7A0C724.P001/REF.pdf

الاتاحة: https://serval.unil.ch/notice/serval:BIB_C9A7B7A0C724
https://doi.org/10.1080/09546634.2020.1782317
https://serval.unil.ch/resource/serval:BIB_C9A7B7A0C724.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_C9A7B7A0C7243

المؤلفون: Reenaers, Catherine, Louis, Edouard

المصدر: Revue Médicale de Liège, 77 (5-6), 323-329 (2022-05)

مصطلحات موضوعية: Tumor Necrosis Factor Inhibitors, FU77B4U5Z0 (Ustekinumab), Colitis, Ulcerative/drug therapy, Crohn Disease, Humans, Inflammatory Bowel Diseases/drug therapy, Ustekinumab/therapeutic use, New biologics, Small molecules, Treat, Ulcerative colitis, Crohn’s disease, target, to, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

Relation: https://rmlg.uliege.be/article/3625?lang=en; urn:issn:0370-629X; urn:issn:2566-1566; https://orbi.uliege.be/handle/2268/301022; info:hdl:2268/301022; info:pmid:35657190

الاتاحة: https://orbi.uliege.be/handle/2268/301022
https://orbi.uliege.be/bitstream/2268/301022/1/Advances%20in%20the%20management%20of%20IBD_C-Reenaers_2022_77_5-6_RMLg.pdf

المؤلفون: Inês Raposo, Andreia Bettencourt, Luiz Leite, Manuela Selores, Tiago Torres

المصدر: Acta Médica Portuguesa, Vol 32, Iss 3, Pp 214-218 (2019)

مصطلحات موضوعية: Biological Products/therapeutic use, Psoriasis/drug therapy, Ustekinumab/therapeutic use, Medicine, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10728; https://doaj.org/toc/0870-399X; https://doaj.org/toc/1646-0758

URL الوصول: https://doaj.org/article/82c5c712cb1a4d908dfc43ee5d091385

المؤلفون: Chandy, Rithi J., Chokshi, Aditi, Tan, Isabella, Feldman, Steven R.

المصدر: Chandy , R J , Chokshi , A , Tan , I & Feldman , S R 2024 , ' Biologics for Treatment of Pityriasis Rubra Pilaris : A Literature Review ' , Journal of Cutaneous Medicine and Surgery , vol. 28 , no. 3 , pp. 269-275 . https://doi.org/10.1177/12034754241238735

مصطلحات موضوعية: biologics, pityriasis rubra pilaris, TNF inhibitor and IL12/23 inhibitor, treatment, Pityriasis Rubra Pilaris/drug therapy, Humans, Antibodies, Monoclonal, Humanized/therapeutic use, Ustekinumab/therapeutic use, Biological Products/therapeutic use, Dermatologic Agents/therapeutic use

الاتاحة: https://portal.findresearcher.sdu.dk/da/publications/6e4e3f1f-6f72-499e-95f9-40e9c9d6c9be
https://doi.org/10.1177/12034754241238735

المؤلفون: Ramos Pinheiro, R, Diamantino, F, Cabete, J, Brasileiro, A, Baptista, J, Paiva Lopes, MJ

المساهمون: Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE

مصطلحات موضوعية: HSAC DER, Adolescent, Child, Adalimumab / therapeutic use, Biological Products / adverse effects, Biological Products / therapeutic use, Humans, Female, Male, Child, Preschool, Dermatologic Agents / adverse effects, Dermatologic Agents / therapeutic use, Drug Substitution / trends, Etanercept / therapeutic use, Infliximab / therapeutic use, Psoriasis / drug therapy, Retrospective Studies, Severity of Illness Index, Ustekinumab / therapeutic use

وصف الملف: application/pdf

Relation: Int J Dermatol . 2017 Dec;56(12):1461-1464.

الاتاحة: http://hdl.handle.net/10400.17/4709

المؤلفون: Biemans, Vince B C, Sleutjes, Jasmijn A M, de Vries, Annemarie C, Bodelier, Alexander G L, Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A, van der Meulen-de Jong, Andrea E, de Boer, Nanne K H, Srivastava, Nidhi, West, Rachel L, Römkens, Tessa E H, Horjus Talabur Horje, Carmen S, Jansen, Jeroen M, van der Woude, C Janneke, Hoekstra, Jildou, Weersma, Rinse K, van Schaik, Fiona D M, Hoentjen, Frank, Pierik, Marieke J, Dutch Initiative on Crohn and Colitis (ICC)

المساهمون: MS MDL 1, Infection & Immunity

مصطلحات موضوعية: real world, tofacitinib, ulcerative colitis, Prospective Studies, Humans, Middle Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Male, Pyrroles/therapeutic use, Treatment Outcome, Pyrimidines/therapeutic use, Crohn Disease/drug therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Piperidines/therapeutic use, Colitis, Ulcerative/drug therapy, Protein Kinase Inhibitors/therapeutic use, Adult, Female, Registries, Ustekinumab/therapeutic use, Netherlands/epidemiology, Gastroenterology, Pharmacology (medical), Hepatology, Journal Article, Observational Study

وصف الملف: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/439570

الاتاحة: https://dspace.library.uu.nl/handle/1874/439570

المؤلفون: Anne Grosen, Emanuelle Bellaguarda, Ingela Liljeqvist-Soltic, Mette Mejlby Hansen, Anne-Bine Skytte, Mette Julsgaard, Stephen B Hanauer, Jens Kelsen

المصدر: Grosen, A, Bellaguarda, E, Liljeqvist-Soltic, I, Mejlby Hansen, M, Skytte, A-B, Julsgaard, M, Hanauer, S B & Kelsen, J 2022, ' Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy ', Inflammatory Bowel Diseases, vol. 28, no. 10, pp. 1603-1606 . https://doi.org/10.1093/ibd/izac028

مصطلحات موضوعية: Male, Gastroenterology, DNA, Inflammatory Bowel Diseases, Spermatozoa, Ustekinumab/therapeutic use, ustekinumab, inflammatory bowel disease, CHROMATIN-STRUCTURE ASSAY, Semen, Inflammatory Bowel Diseases/drug therapy, sperm DNA integrity, Immunology and Allergy, FERTILITY, Humans, Ustekinumab

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cad9c4596a406a02e62ed6defb8d934
https://pure.au.dk/portal/da/publications/normal-sperm-dna-integrity-in-patients-with-inflammatory-bowel-disease-on-ustekinumab-maintenance-therapy(ecf9d55e-a408-489a-bbed-93fe51baf2b7).html

المساهمون: S W Youn, B R Kim, S Cho, S J Seo, E S Lee, J Y Roh, G S Choi, M G Lee, MARCOPOLO investigators, Lee, Min Geol

مصطلحات موضوعية: Dermatologic Agents / therapeutic use, Humans, Nail Diseases / drug therapy, Nail Diseases / etiology, Psoriasis / complications, Psoriasis / drug therapy, Severity of Illness Index, Treatment Outcome, Ustekinumab / therapeutic use

Relation: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; J01783; OAK-2020-02168; https://ir.ymlib.yonsei.ac.kr/handle/22282913/178342; T201706189; JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, Vol.31(6) : e298-e299, 2017-06

الاتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/178342
https://doi.org/10.1111/jdv.14083
https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.14083

المساهمون: College of Medicine, Dept. of Dermatology, Young Ji Hwang, Sang Woong Youn, Bo Ri Kim, Dae Young Yu, Youngdoe Kim, Antonio Pires, Soyun Cho, Seong Jun Seo, Eun So Lee, Joo Young Roh, Gwang Seong Choi, Min Geol Lee, the MARCOPOLO investigators, Lee, Min Geol

مصطلحات موضوعية: Adult, Chronic Disease, Dermatologic Agents/therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Psoriasis/drug therapy, Treatment Outcome, Ustekinumab/therapeutic use, clinical factors, clinical response, comorbidities, psoriasis, ustekinumab

Relation: JOURNAL OF DERMATOLOGY; J01372; OAK-2017-05377; https://ir.ymlib.yonsei.ac.kr/handle/22282913/160968; T201703729; JOURNAL OF DERMATOLOGY, Vol.44(5) : 560-566, 2017

الاتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/160968
https://doi.org/10.1111/1346-8138.13681
https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.13681

المؤلفون: Feldmeyer, L., Mylonas, A., Demaria, O., Mennella, A., Yawalkar, N., Laffitte, E., Hohl, D., Gilliet, M., Conrad, C.

المصدر: JAMA dermatology, vol. 153, no. 4, pp. 304-308

مصطلحات موضوعية: Adult, Biopsy, Cytokines/genetics, Dermatologic Agents/pharmacology, Dermatologic Agents/therapeutic use, Follow-Up Studies, Humans, Interleukin-23/genetics, Male, Pityriasis Rubra Pilaris/drug therapy, Pityriasis Rubra Pilaris/genetics, Pityriasis Rubra Pilaris/pathology, Psoriasis/pathology, RNA, Messenger/metabolism, Th17 Cells/metabolism, Time Factors, Treatment Outcome, Up-Regulation, Ustekinumab/pharmacology, Ustekinumab/therapeutic use

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/28122069; info:eu-repo/semantics/altIdentifier/eissn/2168-6084; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_83DD35FFCF799; https://serval.unil.ch/notice/serval:BIB_83DD35FFCF79; https://serval.unil.ch/resource/serval:BIB_83DD35FFCF79.P001/REF.pdf

الاتاحة: https://serval.unil.ch/notice/serval:BIB_83DD35FFCF79
https://doi.org/10.1001/jamadermatol.2016.5384
https://serval.unil.ch/resource/serval:BIB_83DD35FFCF79.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_83DD35FFCF799

المؤلفون: Manlay, Luc, Boschetti, Gilles, Pereira, Bruno, Flourié, Bernard, Dapoigny, Michel, Reymond, Maud, Sollelis, Elisa, Gay, Claire, Boube, Mathilde, Buisson, Anthony, Nancey, Stéphane

المساهمون: Service Hépato-Gastro-Entérologie CHU Clermont-Ferrand, CHU Estaing Clermont-Ferrand, CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Spécialités médicales et chirurgicales CHU Clermont-Ferrand, CHU Clermont-Ferrand, Service d'Hépatogastroentérologie CHU Lyon-Sud, Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Biostatistiques, Télématiques, Traitement de l’image CHU Clermont-Ferrand, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Santé Publique CHU Clermont-Ferrand, CHU Clermont-Ferrand-CHU Clermont-Ferrand, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA)

المصدر: ISSN: 0953-0673.

مصطلحات موضوعية: MESH: Antibodies, Monoclonal, Humanized / therapeutic use, MESH: Crohn Disease* / drug therapy, MESH: Treatment Outcome, MESH: Tumor Necrosis Factor Inhibitors, MESH: Ustekinumab* / therapeutic use, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences

Relation: info:eu-repo/semantics/altIdentifier/pmid/33909920; PUBMED: 33909920; WOS: 000644978000001

الاتاحة: https://hal.inrae.fr/hal-03299886
https://doi.org/10.1111/apt.16377

المؤلفون: Krabbe, Simon, Grøn, Kathrine L, Glintborg, Bente, Nørgaard, Mette, Mehnert, Frank, Jarbøl, Dorte E, Østergaard, Mikkel, Hetland, Merete L

المصدر: Krabbe , S , Grøn , K L , Glintborg , B , Nørgaard , M , Mehnert , F , Jarbøl , D E , Østergaard , M & Hetland , M L 2021 , ' Risk of serious infections in arthritis patients treated with biological drugs : a matched cohort study and development of prediction model ' , Rheumatology , vol. 60 , no. 8 , pp. 3834-3844 . https://doi.org/10.1093/rheumatology/keaa876

مصطلحات موضوعية: biologicals, epidemiology, infection, Area Under Curve, Humans, Middle Aged, Arthritis, Rheumatoid/drug therapy, Male, Psoriatic/drug therapy, Case-Control Studies, Spondylarthropathies/drug therapy, Tumor Necrosis Factor Inhibitors/therapeutic use, Adult, Female, Ustekinumab/therapeutic use, Clinical Decision Rules, Severity of Illness Index, Antibodies, Monoclonal, Humanized/therapeutic use, Proportional Hazards Models, Logistic Models, Hospitalization, Biological Products/therapeutic use, Infections/epidemiology, ROC Curve, Aged, Antirheumatic Agents/therapeutic use, Rituximab/therapeutic use

Relation: https://portal.findresearcher.sdu.dk/da/publications/a09b27dd-2484-4c07-b37f-190e5d3504b7

الاتاحة: https://portal.findresearcher.sdu.dk/da/publications/a09b27dd-2484-4c07-b37f-190e5d3504b7
https://doi.org/10.1093/rheumatology/keaa876

المؤلفون: Luc Manlay, Gilles Boschetti, Bruno Pereira, Bernard Flourié, Michel Dapoigny, Maud Reymond, Elisa Sollelis, Claire Gay, Mathilde Boube, Anthony Buisson, Stéphane Nancey

المساهمون: Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service d'Hépatogastroentérologie [CHU Lyon-Sud], Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Molé, Christine, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 53 (12), pp.1289-1299. ⟨10.1111/apt.16377⟩

مصطلحات موضوعية: Adult, medicine.medical_specialty, medicine.medical_treatment, Antibodies, Monoclonal, Humanized, Gastroenterology, Vedolizumab, MESH: Ustekinumab* / therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Refractory, Crohn Disease, Internal medicine, Ustekinumab, medicine, Clinical endpoint, Humans, Pharmacology (medical), 030212 general & internal medicine, MESH: Treatment Outcome, Crohn's disease, Hepatology, business.industry, MESH: Antibodies, Monoclonal, Humanized / therapeutic use, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Bowel resection, Odds ratio, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Treatment Outcome, MESH: Crohn Disease* / drug therapy, Monoclonal, 030211 gastroenterology & hepatology, MESH: Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor Inhibitors, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2652049eb780af3af66c93ab6ce48e7
https://pubmed.ncbi.nlm.nih.gov/34170547

المصدر: BADBIR Study Group 2019 , ' HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis ' , The Journal of allergy and clinical immunology , vol. 143 , no. 6 , pp. 2120-2130 . https://doi.org/10.1016/j.jaci.2018.11.038

مصطلحات موضوعية: Adalimumab/therapeutic use, Adult, Alleles, Biological Therapy/methods, Biomarkers, Pharmacological, Female, Genetic Predisposition to Disease, Genotype, HLA-C Antigens/genetics, Humans, Male, Middle Aged, Polymorphism, Genetic, Predictive Value of Tests, Prognosis, Psoriasis/diagnosis, Severity of Illness Index, Treatment Outcome, Ustekinumab/therapeutic use, Young Adult

الاتاحة: https://research.manchester.ac.uk/en/publications/72e9aada-4eba-415f-9029-02e4205d4935
https://doi.org/10.1016/j.jaci.2018.11.038

المؤلفون: Lone Skov, T N Dam, Lars Iversen, Lone Hvid, Alexander Egeberg, Robert Gniadecki, L.E. Bryld

المصدر: Egeberg, A, Iversen, L, Gniadecki, R, Hvid, L, Dam, T N, Bryld, L E & Skov, L 2017, ' Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis : nationwide results from the DERMBIO registry ', Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 7, pp. 1183–1187 . https://doi.org/10.1111/jdv.14200
Egeberg, A, Iversen, L, Gniadecki, R, Hvid, L, Dam, T N, Bryld, L E & Skov, L 2017, ' Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis-nationwide results from the DERMBIO registry ', Journal of the European Academy of Dermatology and Venereology, vol. 31, pp. 1183-1187 . https://doi.org/10.1111/jdv.14200

مصطلحات موضوعية: Male, medicine.medical_specialty, Denmark, Antibodies, Monoclonal/therapeutic use, Dermatology, Comorbidity, Antibodies, Monoclonal, Humanized, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis Area and Severity Index, Psoriasis, Severity of illness, Ustekinumab, Journal Article, medicine, Humans, Registries, Dermatologic Agents/therapeutic use, business.industry, Antibodies, Monoclonal, Dermatology Life Quality Index, medicine.disease, Ustekinumab/therapeutic use, Clinical trial, Infectious Diseases, 030220 oncology & carcinogenesis, Secukinumab, Female, Dermatologic Agents, business, Psoriasis/complications, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f697acc39ed908c4cad2c550f45968
https://portal.findresearcher.sdu.dk/da/publications/5433ebc2-5d79-4515-a0b6-ae03788d8dae